Xencor, Inc. (NASDAQ:XNCR) Given Average Rating of “Buy” by Analysts

Xencor, Inc. (NASDAQ:XNCRGet Rating) has received an average rating of “Buy” from the fourteen research firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation, ten have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $48.89.

Several equities analysts recently commented on XNCR shares. JPMorgan Chase & Co. started coverage on Xencor in a research report on Wednesday, September 21st. They set an “overweight” rating and a $37.00 price target on the stock. Cowen began coverage on Xencor in a research report on Tuesday, December 6th. They issued an “outperform” rating on the stock. Cowen began coverage on Xencor in a research report on Tuesday, December 6th. They issued an “outperform” rating on the stock. Raymond James raised Xencor from an “outperform” rating to a “strong-buy” rating and set a $58.00 target price on the stock in a research report on Thursday, October 13th. Finally, Canaccord Genuity Group cut their target price on Xencor from $50.00 to $48.00 in a research report on Wednesday, November 9th.

Xencor Stock Performance

Shares of NASDAQ:XNCR opened at $28.30 on Friday. Xencor has a 1 year low of $19.35 and a 1 year high of $37.18. The stock has a market capitalization of $1.70 billion, a P/E ratio of 58.96 and a beta of 0.65. The stock has a 50-day simple moving average of $27.97 and a 200-day simple moving average of $28.16.

Xencor (NASDAQ:XNCRGet Rating) last released its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.77) by $0.22. The firm had revenue of $27.30 million for the quarter, compared to analyst estimates of $15.33 million. Xencor had a return on equity of 4.04% and a net margin of 10.07%. Analysts predict that Xencor will post -1.61 earnings per share for the current year.

Insider Activity at Xencor

In related news, CMO Allen Yang sold 3,737 shares of the company’s stock in a transaction that occurred on Monday, December 19th. The stock was sold at an average price of $27.00, for a total transaction of $100,899.00. Following the sale, the chief marketing officer now directly owns 63,521 shares of the company’s stock, valued at approximately $1,715,067. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 4.23% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. grew its stake in Xencor by 0.8% during the 3rd quarter. BlackRock Inc. now owns 10,006,966 shares of the biopharmaceutical company’s stock worth $259,982,000 after buying an additional 83,291 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in Xencor by 12.7% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 6,599,071 shares of the biopharmaceutical company’s stock worth $180,617,000 after buying an additional 744,569 shares during the last quarter. Vanguard Group Inc. grew its stake in Xencor by 2.4% during the 3rd quarter. Vanguard Group Inc. now owns 6,561,500 shares of the biopharmaceutical company’s stock worth $170,467,000 after buying an additional 153,529 shares during the last quarter. Primecap Management Co. CA grew its stake in Xencor by 18.7% during the 3rd quarter. Primecap Management Co. CA now owns 5,690,231 shares of the biopharmaceutical company’s stock worth $147,832,000 after buying an additional 895,179 shares during the last quarter. Finally, State Street Corp grew its stake in Xencor by 9.4% during the 2nd quarter. State Street Corp now owns 3,247,981 shares of the biopharmaceutical company’s stock worth $88,897,000 after buying an additional 279,080 shares during the last quarter. 98.99% of the stock is currently owned by institutional investors.

About Xencor

(Get Rating)

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

Featured Stories

Analyst Recommendations for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.